Abstract: In one aspect, separator-free energy storage devices are disclosed. Such devices comprise a first electrode and a second electrode. In some embodiments, the first electrode is opposite the second electrode. The first and/or second electrodes are formed from a nanocomposite material. The nanocomposite material includes plurality of carbon nanostructures, each of which is at least partially coated with a layer of material comprising a transition metal oxide. In some embodiments, the coating layer is uniform or substantially uniform in one or more properties.

Abstract: The presently disclosed subject matter provides synergistic mixtures for inducing hygienic behavior in honey bees and related compositions and methods.

Abstract: The presently disclosed subject matter relates generally to a highly ionically conductive solid electrolyte membrane and to batteries comprising such solid electrolyte membrane.

Abstract: The invention is directed to methods and systems for early detection of viral diseases, and more specifically to systems and methods for early detection of viral diseases that are capable of detecting very low viral loads, such as for example and not limitation, SARS-CoV-2 loads.

Abstract: The devices and methods described herein push forward the resolution limits of directed self-assembly (DSA) technology for advanced device applications. Specifically described herein, are compositions of bioinspired DSA materials and methods using these bioinspired DSA materials to form sub-7 nm line-space patterns and to achieve functional nanoscopic structures, e.g., conducting nanowires on a substrate.

Abstract: This disclosure is directed to non-aromatic difluoro analogues of resorcylic acid lactones, pharmaceutical compositions comprising non-aromatic difluoro analogues of resorcylic acid lactones, and methods of treatment comprising non-aromatic difluoro analogues of resorcylic acid lactones.

Abstract: In one aspect, nanoplasmonic devices are described herein. In some embodiments, a nanoplasmonic device comprises a radiation transmissive substrate, a metal layer positioned on the substrate and at least one aperture extending through the metal layer to the radiation transmissive substrate, wherein width of the aperture decreases with increasing depth of the aperture.

Abstract: The present invention provides compounds having a CB1 receptor-binding moiety and a directing moiety. In related aspects, the invention provides pharmaceutical compositions containing compounds of the invention, methods for inhibiting a pathway modulated in part by the CB1 receptor activity, and methods for treating a condition or disorder mediated in part by CB1 receptor activity. In certain embodiments, the compounds are compounds of Formula I. Methods of preparing compounds of Formula I are also described. In another aspect, the invention provides methods of identifying a selective agonist of the beta-arrestin pathway over the G-protein pathway.

Abstract: The presently disclosed subject matter provides tritriacontene compositions for inducing hygienic behavior in honey bees; mite-infested brood extract compositions for inducing hygienic behavior in honey bees; methods of inducing hygienic behavior in honey bees; methods of selecting one or more honey bee(s) exhibiting hygienic behavior, and methods for assessing the degree of hygienic behavior within a honey bee colony.

Abstract: The presently disclosed subject matter provides tritriacontene compositions for inducing hygienic behavior in honey bees; mite-infested brood extract compositions for inducing hygienic behavior in honey bees; methods of inducing hygienic behavior in honey bees; methods of selecting one or more honey bee(s) exhibiting hygienic behavior, and methods for assessing the degree of hygienic behavior within a honey bee colony.

Abstract: This disclosure is directed to non-aromatic difluoro analogues of resorcylic acid lactones, pharmaceutical compositions comprising non-aromatic difluoro analogues of resorcylic acid lactones, and methods of treatment comprising non-aromatic difluoro analogues of resorcylic acid lactones.

Abstract: The presently disclosed subject matter relates generally to antifungal nanofibrous materials and the use of such materials.

Abstract: The present invention provides compounds having a CB1 receptor-binding moiety and a directing moiety. In related aspects, the invention provides pharmaceutical compositions containing compounds of the invention, methods for inhibiting a pathway modulated in part by the CB1 receptor activity, and methods for treating a condition or disorder mediated in part by CB1 receptor activity. In certain embodiments, the compounds are compounds of Formula I. Methods of preparing compounds of Formula I are also described. In another aspect, the invention provides methods of identifying a selective agonist of the beta-arrestin pathway over the G-protein pathway.

Abstract: A system and method for determining the presence and level of allergy indicators in a human fluid sample such as, but not limited to, blood serum and saliva, is disclosed. In another embodiment, the method may assess a level of allergens in a consumable product. The system and method may make use of functionalized magnetic nanoparticles that have modified surfaces suitable for attracting allergy indicators from human fluid sample and allergens from consumable products. The system and method may provide a minimally invasive assessment of allergy indicators to determine whether one is allergic to a substance.

Abstract: Embodiments of the disclosed invention encompass physiological and behavioral measurement techniques that can index dynamical diseases. Embodiments include a system and method for continuously measuring locomotor patterns which may be in combination with classic summary measures of performance, compared to summary measures alone. A unique classification of mathematics may be employed to prescribe certain patterns which correspond to locomotor patterns of a test subject.

Abstract: The present invention provides compounds having a CB1 receptor-binding moiety and a directing moiety. In related aspects, the invention provides pharmaceutical compositions containing compounds of the invention, methods for inhibiting a pathway modulated in part by the CB1 receptor activity, and methods for treating a condition or disorder mediated in part by CB1 receptor activity. In certain embodiments, the compounds are compounds of Formula I. Methods of preparing compounds of Formula I are also described. In another aspect, the invention provides methods of identifying a selective agonist of the beta-arrestin pathway over the G-protein pathway.

Abstract: A method of determining the susceptibility to ventricular arrhythmias in a subject, the method including determining a reserve of refractoriness (RoR) and a reserve of memory (RoM) and combining the reserve of refractoriness (RoR) and the reserve of memory (RoM) to produce a metric of stability-of-propagation reserve (SoPR) in the subject, a higher value of SoPR indicating lower susceptibility to ventricular arrhythmias in the subject. Systems and apparatus for carrying out the method are also described.

Abstract: The present invention provides compounds having a CB1 receptor-binding moiety and a directing moiety. In related aspects, the invention provides pharmaceutical compositions containing compounds of the invention, methods for inhibiting a pathway modulated in part by the CB1 receptor activity, and methods for treating a condition or disorder mediated in part by CB1 receptor activity. In certain embodiments, the compounds are compounds of Formula I. Methods of preparing compounds of Formula I are also described. In another aspect, the invention provides methods of identifying a selective agonist of the beta-arrestin pathway over the G-protein pathway.

Abstract: The present invention provides a method of stimulating an excitable tissue (e.g., in vitro, in vivo) with a primary electrical stimulus through a primary electrode at a primary stimulation frequency, to produce a propagating action potential in the excitable tissue. The invention is carried out by concurrently stimulating the excitable tissue with a secondary electrical stimulus through at least one secondary electrode at a secondary stimulation frequency. The primary and secondary stimulation frequencies are preferably different from one another. The secondary electrical stimulus preferably has an amplitude not more than one third that of the primary electrical stimulus. Preferably, propagation of the action potential in the excitable tissue is enhanced (e.g., when propagation of action potentials in the tissue is otherwise unstable, partially blocked, or fully blocked). Apparatus for carrying out the method is also described.

Abstract: Disclosed are arrays for monitoring ecosystems, such as bodies of water, and methods and systems for making such arrays. In one embodiment, the array may include a plurality of oligonucleotides immobilized at known locations on a substrate, such that each location on the array is an oligonucleotide having a sequence derived from a single, predetermined operational taxonomic unit (OTU). The sequences immobilized on the array may be from known, or unknown organisms. Also disclosed are methods for identifying and isolating bioindicators diagnostic of specific ecosystems. The arrays and bioindicators of the invention may be used for rapid, and continual monitoring of ecosystems.